This agent targets the overexpression of histone deacetylase (HDAC) or the aberrant recruitment of HDACs to oncogenic transcription factors in cancer cells. Vorinostat was approved on October 6, 2006, for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease following 2 systemic therapies.
Zolinza
VorinostatMerckFirst-in-class histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
This agent targets the overexpression of histone deacetylase (HDAC) or the aberrant recruitment of HDACs to oncogenic transcription factors in cancer cells. Vorinostat was approved on October 6, 2006, for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease following 2 systemic therapies.
Safety. Pulmonary embolism and deep vein thrombosis have been reported in association with vorinostat. Patients receiving vorinostat therapy should be monitored for the pertinent signs and symptoms of these conditions. Dose-related thrombocytopenia and anemia have occurred with vorinostat and may require dose modification or discontinuation of therapy. Vorinostat therapy has been associated with gastrointestinal disturbances (eg, nausea, vomiting, and diarrhea). As such, patients may require antiemetics, antidiarrheals, and/or fluid or electrolyte replacement when taking the drug. Hyperglycemia has been observed in association with vorinostat therapy, necessitating the potential adjustment of diet and/or dosing. Vorinostat has been associated with prolongation of the QTc interval. Taking this into consideration, patients' electrolytes and electrocardiograms (ECGs) should be monitored at baseline and periodically during treatment. The most common adverse events associated with vorinostat therapy include diarrhea, fatigue, nausea, thrombocytopenia, anorexia, and dysgeusia.
Dosing. The recommended dose of vorinostat is 400 mg orally once daily with food. If a patient is intolerant to therapy, the dose may be reduced to 300 mg once daily with food. If necessary, the dose may be further reduced to 300 mg once daily with food for 5 consecutive days each week.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
Joseph Zabinski Advocates for Patient Trust in AI Adoption in Dermatology Care
April 18th 2024Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.
Read More